Hasselt, Sep 30, 2022 – Extra Horizon, a leader in the Medical Backend-as-a-Service (MBaaS) market, has officially demerged from its parent company, Qompium nv. For almost a decade now, Qompium has been a leading pioneer in the Software as a Medical Device (SaMD) market. Up until now, the company consisted of two business units, Fibricheck (a medical app that detects heart rhythm disorders) and Extra Horizon (a medical backend-as-a-service that accelerates the launch of medical apps for other eHealth companies).
This demerger clears the path for both organisations to set their own growth path. Although both FibriCheck and Extra Horizon as products are operating in the medical software space, they are servicing different customer bases. Whereas FibriCheck serves doctors and patients as their end users, both directly and through partnerships and integrations, Extra Horizon services other medical software startups.
Lars Grieten, CEO of Qompium nv explains: “When we started building FibriCheck, we quickly realised that a lot of our time and resources were being invested in making and keeping our product up to date with compliance requirements, scalability needs and offering flexibility. We took the decision to re-invent the way of working and built a platform, Extra Horizon, that services all the needs to support the current and future roadmap of FibriCheck. It quickly became clear that Extra Horizon also brings tremendous value to other companies that aim to develop and commercialise medical applications. By spinning off Extra Horizon, we are proud to see this dream become a reality. Next to that, the demerger allows FibriCheck to maximise the focus of our engineering resources on a roadmap that maximises value-building for our end-users.”